Home › Atrial Fibrillation › NCT07535268
REPRESENT-PF Registry
Prospective Multicenter Registry on the Clinical Outcomes and Safety of PFA for Atrial Fibrillation in Underrepresented Minorities (REPRESENT-PF Registry)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * All consecutive patients classified as racial or ethnic minorities undergoing ablation using Boston Scientific FDA approved PFA catheters for AF will be included. * De novo ablation for symptomatic paroxysmal and persistent AF (Age ≥ 18) (unless it is a repeat for a patient whose index procedure is also in the registry) who are deemed to be candidates for AF ablation by the investigator. * Able and willing to participate in baseline and follow up evaluation over the study period * Willing and able to provide informed consent, if applicable. Exclusion Criteria: * Enrolled in an investigational drug or device clinical trial or any other trial with outlined treatment plan * Long standing persistent AF (AF \> 1 year duration) * Repeat ablation, unless index ablation procedure was in the REPRESENT-PF registry * Any known contra-indication to ablation procedure at the discretion of the investigator
About the study
This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of care.
What is being tested
- FARAWAVE Pulsed Field Ablation Catheter (device)
Sponsor: Vivek Reddy · Participants: 275 · Started: Mar 30, 2026
Contact the study team
- Devin Chamberlain · Phone: (646) 984-1049
Official record on ClinicalTrials.gov — NCT07535268
Locations in the U.S.
| New York | The Mount Sinai Hospital, New York |
| Virginia | Valley Health System, Winchester |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.